多西他赛联合卡培他滨治疗老年晚期胃癌的疗效分析  

Docetaxel in Combination with Xeloda in the Treatment of Elderly Patients with Advanced Gastric Cancer

作　　者：邱宇安[1] 刘洪涛 陈火国[1] 靳文剑[1] 贺文兴[1] 洪道显[1] 尹福根[1] 

机构地区：[1]江西省肿瘤医院内四科,330029 [2]江西省南康市人民医院,341400

出　　处：《实用癌症杂志》2009年第6期618-620,共3页The Practical Journal of Cancer

摘　　要：目的评价多西他赛联合卡培他滨方案治疗老年晚期胃癌的疗效和毒性反应。方法30例老年晚期胃癌患者接受多西他赛75mg／m2静脉滴注，第1天；卡培他滨2000mg／m2，分两次口服，第1～14天；3周为1个周期。治疗至少2个周期后评价疗效及不良反应。结果可评价疗效者30例，治疗后获得完全缓解（CR）1例，部分缓解（PR）12例。稳定（SD）10例，进展（PD）7例，总有效率（R．R）为43．3％（13／30）。中位疾病进展时间（TTP）为5．2个月，中位生存期（MST）为9．0个月。临床获益率为73．3％。主要不良反应为骨髓抑制、脱发、腹泻、手足综合征。结论多西他赛联合卡培他滨治疗老年晚期胃癌具有较好的疗效，且不良反应可耐受。Objective To evaluate the efficacy and toxicities of docetaxel plus xeloda in the treatment of elderly patients with advanced gastric cancer. Methods 30 elderly patients with advanced gastric cancer were treated with docetaxel 75 mg/m2 on dayl and xeloda 2 000 mg/m2 （ in two divided oral doses） for 14 days. The chemotherapy repeated every 3 weeks. Efficacy and toxicities were reviewed after at least 2 cycles of chemotherapy. Results All the patients could be included for response rate and the overall response rate was 43.3% （13/30） with 1 case of complete response（CR） and 12 of partial response （ PR）, 10 of steadiness（SD） and 2 of progressive disease （PD）. Median time to progress （TFP） was 5.2 months, median survival time （MST） was 9.0 months. The clinical benefit rate was 73.3 %. The main adverse reactions were myelosuppression, alopecia, diarrhea,hand-foot syndrome. Conclusion The combination of docetaxel and Xeloda is well tolerated and effecitive in the treatment of elderly patients with advanced gastric cancer.

关 键 词：胃癌 化学治疗 多西他赛 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]